FDA Approves Lebrikizumab for Atopic Dermatitis

More than 1000 people age 12 years and older were enrolled in pivotal trials of the IL-13 inhibitor.
Medscape Medical News

source https://www.medscape.com/viewarticle/fda-approves-lebrikizumab-atopic-dermatitis-2024a1000gpu?src=rss

Comments

Popular posts from this blog

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?

New AAFP practice guideline sets blood pressure targets for adults with hypertension